These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 23554447

  • 1. Cisplatin resistance associated with PARP hyperactivation.
    Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, Sukkurwala AQ, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Dessen P, Saparbaev M, Soria JC, Castedo M, Kroemer G.
    Cancer Res; 2013 Apr 01; 73(7):2271-80. PubMed ID: 23554447
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
    Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G.
    Cell Cycle; 2013 Mar 15; 12(6):877-83. PubMed ID: 23428903
    [Abstract] [Full Text] [Related]

  • 4. MCL-1 dependency of cisplatin-resistant cancer cells.
    Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Castedo M, Kroemer G.
    Biochem Pharmacol; 2014 Nov 01; 92(1):55-61. PubMed ID: 25107702
    [Abstract] [Full Text] [Related]

  • 5. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA, Li G, Harvey D, Khuri FR, Vertino PM, Brandes JC.
    Oncotarget; 2015 Oct 13; 6(31):30773-86. PubMed ID: 26356822
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
    Majuelos-Melguizo J, Rodríguez MI, López-Jiménez L, Rodríguez-Vargas JM, Martí Martín-Consuegra JM, Serrano-Sáenz S, Gavard J, de Almodóvar JM, Oliver FJ.
    Oncotarget; 2015 Mar 10; 6(7):4790-803. PubMed ID: 25576921
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y, Gallacchi D, Zhang EY, Reynolds SB, Robinson L, Malinowska IA, Chiou TT, Pereira AM, Li C, Kwiatkowski DJ, Lee PS, Yu JJ.
    Am J Respir Cell Mol Biol; 2014 Dec 10; 51(6):738-49. PubMed ID: 24874429
    [Abstract] [Full Text] [Related]

  • 11. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
    Kim J, Long KE, Tang K, Padanilam BJ.
    Kidney Int; 2012 Jul 10; 82(2):193-203. PubMed ID: 22437413
    [Abstract] [Full Text] [Related]

  • 12. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
    Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA.
    J Pathol; 2011 Aug 10; 224(4):564-74. PubMed ID: 21706479
    [Abstract] [Full Text] [Related]

  • 13. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
    Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P, Lu B, Liu G, Wang Z.
    PLoS One; 2015 Aug 10; 10(5):e0114586. PubMed ID: 25992654
    [Abstract] [Full Text] [Related]

  • 14. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
    Shan L, Li X, Liu L, Ding X, Wang Q, Zheng Y, Duan Y, Xuan C, Wang Y, Yang F, Shang Y, Shi L.
    Oncogene; 2014 Jun 12; 33(24):3205-16. PubMed ID: 23851505
    [Abstract] [Full Text] [Related]

  • 15. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
    Matsunaga T, Yamaji Y, Tomokuni T, Morita H, Morikawa Y, Suzuki A, Yonezawa A, Endo S, Ikari A, Iguchi K, El-Kabbani O, Tajima K, Hara A.
    Free Radic Res; 2014 Nov 12; 48(11):1371-85. PubMed ID: 25156503
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
    Chen S, Liu X, Gong W, Yang H, Luo D, Zuo X, Li W, Wu P, Liu L, Xu Q, Ji A.
    Oncol Rep; 2013 Jan 12; 29(1):260-8. PubMed ID: 23117577
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
    Cho HJ, Kim IK, Park SM, Baek KE, Nam IK, Park SH, Ryu KJ, Choi J, Ryu J, Hong SC, Jeong SH, Lee YJ, Ko GH, Kim J, Won Lee C, Soo Kang S, Yoo J.
    Int J Cancer; 2014 Oct 01; 135(7):1553-63. PubMed ID: 24585459
    [Abstract] [Full Text] [Related]

  • 19. Hydrogen peroxide-induced poly(ADP-ribosyl)ation regulates osteogenic differentiation-associated cell death.
    Robaszkiewicz A, Erdélyi K, Kovács K, Kovács I, Bai P, Rajnavölgyi E, Virág L.
    Free Radic Biol Med; 2012 Oct 15; 53(8):1552-64. PubMed ID: 22940495
    [Abstract] [Full Text] [Related]

  • 20. The role of p38 signaling and poly(ADP-ribosyl)ation-induced metabolic collapse in the osteogenic differentiation-coupled cell death pathway.
    Robaszkiewicz A, Valkó Z, Kovács K, Hegedűs C, Bakondi E, Bai P, Virág L.
    Free Radic Biol Med; 2014 Nov 15; 76():69-79. PubMed ID: 25078118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.